Why the study?
Does clinicopathologic subclassification of malignant fibrous histiocytomas provide prognostic information?
Does clinicopathologic subclassification of malignant fibrous histiocytomas provide prognostic information?
Subclassification of malignant fibrous histiocytomas is clinically important, as pleomorphic soft tissue sarcomas with myogenic differentiation are significantly more aggressive.
May support prognostic subclassification in pleomorphic sarcomas; leaves open impact on therapy.
This retrospective study confirms that most so-called MFH can be subclassified by defined criteria; it provides evidence that such classification is clinically important. Specifically, pleomorphic STS showing myogenic differentiation are significantly more aggressive, a finding that allows planning future therapeutic trials.
No takes yet. Share an insight, caveat, or question.
Fletcher et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: